Page last updated: 2024-08-21

quinazolines and bosutinib

quinazolines has been researched along with bosutinib in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	7 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Botta, M; Brullo, C; Musumeci, F; Schenone, S	2
Dempke, W; Zippel, R	1
Eadens, M; Messersmith, W; Puls, LN	1
Barth, C; Massard, C; Vignot, S	1
Farias-Hesson, E; Finigan, JH; Heasley, LE; Kang, J; Kern, JA; Kim, J; Leach, SM; Mason, RJ; Mishra, R; Ramamoorthy, P; Singleton, KR; Tan, AC; Vasu, VT; Yoo, M	1
Usui, N	1

Reviews

5 review(s) available for quinazolines and bosutinib

Article	Year
Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:8 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines	2010
[SRC kinases in tumor therapy]. Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:10 Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles	2010
Current status of SRC inhibitors in solid tumor malignancies. The oncologist, 2011, Volume: 16, Issue:5 Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles	2011
An update on dual Src/Abl inhibitors. Future medicinal chemistry, 2012, Volume: 4, Issue:6 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles	2012
[Bone targeted therapies: new agents]. Bulletin du cancer, 2013, Volume: 100, Issue:11 Topics: Aniline Compounds; Benzodioxoles; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Dasatinib; Diphosphonates; Humans; Molecular Targeted Therapy; Nitriles; Parathyroid Hormone-Related Protein; Pyrimidines; Quinazolines; Quinolines; RANK Ligand; Receptors, Chemokine; src-Family Kinases; Thiazoles; Transforming Growth Factor beta1	2013

Other Studies

2 other study(ies) available for quinazolines and bosutinib

Article	Year
Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics (Oxford, England), 2014, Sep-01, Volume: 30, Issue:17 Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Sequence Analysis, RNA	2014
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). International journal of hematology, 2017, Volume: 106, Issue:5 Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk	2017

Article

Year

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Bioinformatics (Oxford, England), 2014, Sep-01, Volume: 30, Issue:17

Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Sequence Analysis, RNA

2014

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).

International journal of hematology, 2017, Volume: 106, Issue:5

Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk

2017